Anzeige
Mehr »
Login
Donnerstag, 23.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
InnoCan Pharma: Jetzt in die Doppel-Chance investieren?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A407S6 | ISIN: US60855D3098 | Ticker-Symbol: MOL
München
23.05.24
08:18 Uhr
4,640 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MOLECULIN BIOTECH INC Chart 1 Jahr
5-Tage-Chart
MOLECULIN BIOTECH INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,5204,68011:46
0,0000,00008:00

Aktuelle News zur MOLECULIN BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.05.Moleculin Biotech, Inc.: Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)54- Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin HOUSTON, May 15, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX)...
► Artikel lesen
14.05.Earnings call: Moleculin Biotech optimistic on Annamycin's future2
13.05.Moleculin Biotech GAAP EPS of -$2.021
13.05.Moleculin Biotech, Inc.: Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update133- Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) -...
► Artikel lesen
13.05.Moleculin Biotech, Inc. - 8-K, Current Report-
11.05.Moleculin Biotech Inc reports results for the quarter ended in January - Earnings Summary1
10.05.Moleculin Biotech, Inc. - 10-Q, Quarterly Report1
02.05.Moleculin Biotech, Inc. - 8-K, Current Report2
01.05.Moleculin Biotech, Inc.: Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin53- Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician member HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin...
► Artikel lesen
26.04.Moleculin Biotech, Inc. - 10-K/A, Annual Report4
25.04.JTC Team, LLC: Moleculin Biotech Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team344Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a fully...
► Artikel lesen
25.04.Moleculin Biotech, Inc. - 8-K, Current Report2
18.04.Moleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AML3
18.04.Moleculin Biotech, Inc.: European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)69- Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects...
► Artikel lesen
18.04.Moleculin Biotech, Inc. - 8-K, Current Report1
10.04.Moleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic Effects2
10.04.Moleculin Biotech, Inc.: Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties159Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against established cardiomyocyte culturesResults clearly aligned with lack of drug-related...
► Artikel lesen
08.04.Moleculin Biotech, Inc. - 8-K, Current Report2
27.03.Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML9
27.03.Moleculin Biotech, Inc. - 8-K, Current Report2
Seite:  Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1